Axis for the duration of the study period (n 45 patients), we constructed Kaplan-Meier curves
Axis in the course of the study period (n 45 individuals), we constructed Kaplan-Meier curves for the probability of getting no cost of IFI stratified by antifungal prophylaxis as a time-dependent covariate (Fig. two). Marked variations in the probability of becoming IFI free of charge were evident amongst sufferers who received primary antifungal prophylaxis with voriconazole or posaconazole and sufferers who received an echinocandin, despite the fact that the rates of empirical antifungal therapy use by the two prophylaxis groups were equivalent (32 versus 40 , P 0.41). All-cause mortality prices did not differ among the echinocandinaac.asm.orgAntimicrobial Agents and ChemotherapyPredictive Things for Fungal Amebae Formulation InfectionTABLE 1 Candidate risk aspects for documented IFI in sufferers with AML throughout initially 120 days right after 1st remission-induction chemotherapyDemographicp Male, n ( ) Median age (IQR), yrs Hospitalizationb Median no. of hospitalizations (IQR) Median duration (IQR), days Admission to the HEPA filter area, n ( ) Underlying situations, n ( ) Lung illness or infectiond Concomitant bacterial infectione Cardiovascular disease or situation Diabetes mellitus or hyperglycemiaf History of renal failure or renal dysfunctiong Abnormal liver testsh No. ( ) with other malignancyi No. ( ) chemotherapy naive WHO AML classification,j n ( ) Therapy-related AML MDS-related modifications Recurrent genetic abnormalities Myeloid sarcoma Acute leukemia of ambiguous lineage Not specified Cytogenetic threat group,k n ( ) Favorable Intermediate I Intermediate II Adverse Remission-induction chemotherapy, n ( ) Cytarabine-based regimen Other regimen Investigational chemotherapyl Clofarabine-based regimenm Overall remission Overall remission, n ( )n Neutropenia Neutropenia at begin of prophylaxis, n ( ) Median no. of episodes of neutropenia (IQR) Median duration of neutropenia (IQR), dayso Major antifungal prophylaxis Anti-Aspergillus azole (voriconazole or posaconazole)cTABLE 1 (Continued)Demographicp Documented IFI (n 21) ten (48) 19 (135) No IFI (n 104) 77 (74) 75 (2901) P valueaDocumented IFI (n 21) 7 (33) 63 (570) 1 (1) 21 (149) 8 (38)No IFI (n 104) 62 (60) 65 (513) 2 (1) 31 (229) 35 (34)P valuea 0.05 0.7 0.0.5 (24) 5 (24) eight (38) five (24) 1 (5) 2 (ten) 7 (33) 1621 (80)26 (25) 15 (14) 32 (31) 18 (17) 15 (14) 13 (13) 19 (18) 94103 (91)0.95 0.3 0.46 0.57 0.23 0.76 0.13 0.Anti-Aspergillus azole use, n ( ) Median duration of antiAspergillus azoles (days), IQR Fluconazole Fluconazole use, n ( ) Median duration of fluconazole (days), IQR Echinocandin Echinocandin use, n ( ) Median duration of echinocandins (days), IQRa b0.4 7 (33) five (25) 40 (38) 31 (70) 0.002 17 (81) 11 (71) 66 (63) 17 (98)421 (19) 821 (38) 521 (24) 021 (0) 021 (0) 421 (19)4102 (4) 29102 (28) 20102 (20) 3102 (3) 2102 (two) 44102 (43)0.03 0.46 0.71 0.31 0.37 0.five (24) 1 (five) 7 (33) eight (38)19 (18) 9 (9) 30 (29) 46 (44)0.58 0.65 0.32 0.Univariate Cox regression evaluation. Time-dependent variable. c At-hospital admission or history. d Lung infection at hospital admission or concomitant to AML history. e At-hospital admission or concomitant to AML history as outlined by the patient’s treating doctor according to clinical, microbiology, and antibiotic prescription information. f Diagnosis of diabetes mellitus or induced FGFR Purity & Documentation hyperglycemia (glucose 200 mgdl). g Diagnosis of renal failure or possibly a 50 increase in serum creatinine level. h Diagnosis of liver illness or abnormal liver blood tests (serum alanine aminotransferase andor aspartate aminotransferase levels three.0 upper.
